Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups.

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups.

<p>Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups.</p>

Saved in:

Bibliographic Details
Main Author:	Claire M. Douglas (21238238) (author)
Other Authors:	Marnie Newell (11631607) (author), Susan Goruk (7343036) (author), Kerry S. Courneya (7238747) (author), Sunita Ghosh (102512) (author), Anil A. Joy (4336462) (author), Jaqueline Munhoz (9901827) (author), Catherine J. Field (6706901) (author)
Published:	2025
Subjects:	Medicine Cell Biology Physiology Pharmacology Biotechnology Immunology Cancer Science Policy Biological Sciences not elsewhere classified Chemical Sciences not elsewhere classified resistance training frequency polyunsaturated fatty acids adequately powered studies meeting exercise guidelines aerobic exercise volume xlink "> supplementation reduced side effects metastatic breast cancer evaluate docosahexaenoic acid 4 &# 8201 significantly affect qol current exploratory study dha supplementation improves women undergoing nac docosahexaenoic acid current study breast cancer exploratory outcomes exercise decreased exercise behaviour exercise ), dha supplementation two indices supportive care supplementing women six cycles significantly lower potential therapies measure qol may mitigate better qol administered questionnaires 8 minutes 57 times 49 ).
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	<p>Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups.</p>

Cannot write session to /tmp/vufind_sessions/sess_ki9o011vnbdaih2f2mo69ljp59